Odporność na antybiotyki szczególnie przez bakterie Gram-ujemne, niemal doprowadziło do sytuacji przypominającej kryzys. Nowy antybiotyk Zosurabalpin (RG6006) jest obiecujący. W badaniach przedklinicznych stwierdzono, że jest skuteczny przeciwko lekoopornym bakteriom Gram-ujemnym CRAB.
Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of antybiotyki to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of antybiotyk odporność.
Acinetobacter baumannii is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available antybiotyki. There is an urgent need for an effective antybiotyk against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective antybiotyk. A progress towards this goal has been reported.
Scientists have identified a novel class of antybiotyki namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
Zosurabalpina (RG6006) jest antybiotyk candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-kliniczny trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame antybiotyk-resistance mechanism of CARB suggesting Zosurabalpina ma potencjał.
Hence, human kliniczny trials have been initiated to check for safety and efficacy Zosurabalpina w leczeniu inwazyjnych zakażeń wywołanych przez CRAB.
***
Referencje:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel antybiotyk class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- Hawser S., i wsp 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Kliniczne Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
